Free Trial

Biofrontera Q3 2023 Earnings Report

Biofrontera logo
$1.02 -0.08 (-7.27%)
As of 04:00 PM Eastern

Biofrontera EPS Results

Actual EPS
-$4.64
Consensus EPS
-$4.23
Beat/Miss
Missed by -$0.41
One Year Ago EPS
-$4.60

Biofrontera Revenue Results

Actual Revenue
$8.90 million
Expected Revenue
$8.87 million
Beat/Miss
Beat by +$30.00 thousand
YoY Revenue Growth
N/A

Biofrontera Announcement Details

Quarter
Q3 2023
Time
After Market Closes

Biofrontera Earnings Headlines

Biofrontera Inc. files to sell 5.72M shares of common stock for holders
24/7 Automated Profits in Crypto
What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.
Biofrontera announces 100 RhodoLED XL machines placed in U.S. market
See More Biofrontera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biofrontera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biofrontera and other key companies, straight to your email.

About Biofrontera

Biofrontera (NASDAQ:BFRI), a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

View Biofrontera Profile

More Earnings Resources from MarketBeat